8 trends tracked about this subject — the full history, oldest to newest below.
Eli Lilly has shifted the FDA application timeline for its next-generation obesity drug, retatrutide, to the first quarter of 2027.
Recent analyses suggest weight-loss drugs may not deliver broader improvements to mental health, job prospects, or overall quality of life.
Insured patients are facing challenges accessing GLP-1 weight-loss drugs as coverage policies and payment models shift.
Employers and public health programs are limiting access to GLP-1 obesity drugs due to rising costs and budget constraints.
Eli Lilly's market value surges as Kailera's weight-loss pill faces market setbacks despite successful clinical efficacy in China.
A Yale secret shopper study reveals significant gaps in the online prescribing process for GLP-1 obesity medications.
Starting July 1, 2026, Medicare will cover GLP-1 weight-loss drugs for seniors, marking a significant expansion in obesity treatment access.
Recent data suggests GLP-1 weight-loss medications may provide unexpected fertility benefits for men.